

1

Review therapy goals

Assessment and Progress Report/Patient Dashboard



- Personalized patient goals may be different
- Further action may not be required if personalized goals are met


Metrics and goals

Time in Ranges ¹	mg/dL	Goal
Time Above	250	<5%
Time Above	180	<25%
Time In Range (TIR)	70-180	>70%
Time Below	70	<4%
Time Below	54	<1%
A1C Goal		<7% ²
Coefficient of variation (CV) ¹		<36%
SmartGuard™ Use		≥85%
Sensor Use ³		≥85%

2

If goals are not met, review therapy

Meal Summary and Weekly/Daily Review Report



Review SmartGuard™ target and AIT

- Is SmartGuard™ target set to 100 mg/dL? AIT set to 2h?
- If no, are higher settings warranted?

Time above range is high

- Bolus timing?
- Boluses omitted?
- Insulin to carb ratio (ICR)? (May need to be strengthened if post-meal glucose is high and bolus timing is appropriate)

Time below range is high

- Bolus timing?
- Overestimation of carbs?
- ICR? (May need to increase [to deliver less insulin] if lows are post meal and bolus timing is appropriate)
- Persistent lows without a bolus? (Consider higher SmartGuard™ target)
- Persistent lows after auto correction boluses? (Consider lengthening AIT)
- Exercise? (Consider using or adjusting Temp Target)
- Lows during sleep? (If snacking before bed, a carb ratio change may be needed. Higher target or using temp target could be considered.)

Consistent highs or lows post-meal

- Adjust carb ratio down or up by 10-20% respectively

Inconsistent highs or lows post-meal

- Discuss and assess carb counting skills and consider bolus timing

SmartGuard™ use <85%

- Educate on sensor wear if primary issue, and check for any SmartGuard™ exits (Assessment and Progress Report)


Sensor use <85%

- Educate on sensor use and care and explore reasons for underuse

3

Update Manual mode settings

Device Settings Report/Assessment & Progress Report



Recommendations

- Adjust BG Target: 100-120 mg/dL to match how the SmartGuard™ algorithm is working
 - Adjust ISF: $1800 \div \text{Total Daily Dose (TDD)}$
 - Basal Rates: Ensure Manual mode 24-hour basal total is $\leq 50\%$ of TDD. Check 24hr programmed manual basal on the Assessment & Progress report and adjust if not $\leq 50\%$.
 - Suspend before low 'ON'
- Evaluate Manual mode settings 1-2 weeks after starting SmartGuard™ feature & at every office visit
 - Adjust settings to mirror SmartGuard™ settings

Ways to learn more about MiniMed™ therapies:



Visit <https://www.professional.minimed.com/> for the latest clinical resources, to request an in-service, and to register for upcoming webinars and livestreams

References

1. Battelino T et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 2019; 42: 1593-1603.
2. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes-2023 Diabetes Care 2023;46(1):S97-S110.
3. Battelino T et al. Routine use of continuous glucose monitoring in 10 501 people with diabetes mellitus. Diabet Med 2015. 2(12); 1568-74.

This information is provided for general educational purposes only and should not be considered the exclusive source for this type of information. At all times, it is the professional responsibility of the practitioner to exercise independent clinical judgment in a particular situation.

Important Safety Information for MiniMed™ 780G System:

MiniMed™ 780G System is for type 1 ages 7 and over and type 2 ages 18 and over. Prescription required. **WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day.** For additional safety information and user guides, see <https://bit.ly/MiniMedRisks>.

Important Safety Information for MiniMed Flex™ System:

MiniMed Flex™ System is for type 1 ages 7 and over and type 2 ages 18 and over. Prescription required. **WARNING: Do not use SmartGuard™ feature for people who require less than 8 units or more than 250 units of insulin/day.** For additional safety information and user guides, see <https://bit.ly/MiniMedRisks>.

See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local MiniMed representative.

US-DBA-2600519 © 2026 Medtronic MiniMed, Inc. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and "a" logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2026 Abbott.™*Third-party brands are trademarks of their respective owners.